BioWorld

Merck Sharp & Dohme identifies new TREM2 agonists

Merck Sharp & Dohme LLC has prepared and tested triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of Alzheimer’s disease and neurodegeneration.
BioWorld

Merck Sharp & Dohme describes new RIPK1 inhibitors

Merck Sharp & Dohme LLC has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, ...
Nature

Merck Sharp and Dohme B.V. (MSD BV Haarlem)

No articles found. Merck Sharp and Dohme B.V. (MSD BV Haarlem) did not contribute to any primary research papers from Nature Index journals in the current 12 month window. The following affiliated ...
PharmiWeb

MSD (Merck) to acquire Terns Pharmaceuticals in USD 6.7 billion deal

MSD (Merck) will acquire Terns Pharmaceuticals for approximately USD 6.7 billion, adding investigational leukemia therapy ...
MobiHealthNews

Merck, Telefonica subsidiaries partner to launch London health accelerator

Merck Sharpe and Dohme (MSD), the UK subsidiary of US pharma company Merck and Co., has partnered with Wayan Open Future, a digital startup accelerator run by Spanish telecom company Telefonica to ...
Nature

Merck Sharp and Dohme B.V. (MSD BV Haarlem)

Article ‘Count’ and ‘Share’ for Merck Sharp and Dohme B.V. (MSD BV Haarlem) based on listed parameters only. According to the parameters selected above, there are no articles from Merck Sharp and ...